Predictors of long-term outcome in patients with biopsy proven inflammatory cardiomyopathy
Ohlow Marc-Alexander1, Michel Christoph1, Ting-Hui Chen1
1Department of Cardiology, Zentralklinik, Bad Berka, Germany.
Insights
Older age, short heart failure duration, and symptoms indicate poor prognosis in inflammatory cardiomyopathy (iCM) patients. Younger patients with longer disease duration show excellent outcomes.
Area of Science:
- Cardiology
- Immunology
- Virology
Background:
- Inflammatory cardiomyopathy (iCM) is a serious condition affecting heart function.
- Identifying prognostic indicators is crucial for managing iCM patients.
Purpose of the Study:
- To identify prognostic indicators in patients diagnosed with iCM via endomyocardial biopsy (EMB).
Main Methods:
- Retrospective analysis of 503 iCM patients diagnosed between 2007-2011.
- Combined primary endpoint included cardiac death, aborted sudden cardiac death, ICD shock, LVAD, and heart transplantation.
- Multivariate analysis identified independent predictors of the primary endpoint.
Main Results:
- Viral genomes detected in 79% of patients; inflammation in 44%.
- Independent predictors for the primary endpoint: age ≥ 50 years, presence of symptomatic heart failure, and duration ≤ 28 days.
- Patients < 50 years with > 28 days disease duration and no heart failure symptoms had 100% survival.
Conclusions:
- Symptoms of heart failure, short disease duration, and older age predict poor outcomes in iCM.
- Risk stratification can identify patients with excellent prognosis.
Background:
The objective of this study was to identify prognostic indicators in patients with inflammatory cardiomyopathy (iCM) on endomyocardial biopsy (EMB).
Methods And Results:
Between 2007 and 2011 all consecutive patients with diagnosed with iCM at EMB were retrospectively analyzed. The combined primary endpoint (EP) (1°EP) was cardiac death, aborted sudden cardiac death/appropriate implantable cardioverter defibrillator (ICD) shock, progressive heart failure requiring left ventricular assist device (LVAD) implantation and heart transplantation. 503 patients (mean age 58 ± 12 years, 73% male) were available for analysis. Genomes of cardiotrophic viruses were detected in 396 patients (79%) and immuno-histochemical signs of inflammation were present in 223 individuals (44%). After 3.6 ± 2.4 years of follow-up, cardiac mortality was 3.0% (n = 14) and a total of 8.6% (n = 40) reached the primary endpoint. Independent predictors for the 1°EP were: age ≥ 50 years, presence and duration (≤ 28 days) of symptomatic heart failure. A risk stratification approach based on the results of the multivariate analysis demonstrated that absence of signs and/or symptoms of congestive heart failure in younger (< 50 years) patients with longer (> 28 days) duration of disease appear to have an excellent prognosis with 100% survival and no events during follow-up. The presence of all above mentioned independent risk factors results in an 1°EP occurrence of 35.9%.
Conclusions:
Symptoms of heart failure, short duration of disease, and older age are indicators of poor outcome in patients with iCM.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy VI: Nursing Management


